Atlantic Research Center — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$2,986	2
2023	Research	$1,895	2
2022	Research	$4,953	2
2021	Research	$116,282	5
2020	Research	$139,424	9
2019	Research	$25,741	7

Breakdown

Who paid Research payments · program years 2019–2024

Regeneron Pharmaceuticals, Inc. $265,765 14 payments
GlaxoSmithKline, LLC. $10,478 4 payments
Novartis Pharmaceuticals Corporation $7,049 7 payments
OptiNose US, Inc. $5,218 1 payment
Merck Sharp & Dohme Corporation $2,771 1 payment

Studies the money was for Research payments · program years 2019–2024

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab As Adjunct to Ar101 (Peanut Oral Immunotherapy) $255,531 12 payments
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 Peanut Oral Immunotherapy $10,234 2 payments
A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro $7,518 3 payments
A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day BID in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205. $5,218 1 payment
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of Ligelizumab (Qge031) in the Treatment of Chronic Inducible Urticaria (Cindu) in Adolescents and Adults Inadequately Controlled By H1-Antihistamines $4,078 3 payments
A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy $2,971 4 payments
A Phase 3, 24-Week, Randomized, Double-Blind, Parallel-Group Bayesian $2,960 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 $2,771 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.